6106-07-6
基本信息
O-(4-羟基-3,5-二碘苯基)-3,5-二碘-L-酪氨酸单钠盐五水合物
左旋甲状腺素钠五水合物
3-[4-(4-HYDROXY-3,5-DIIODOPHENOXY)-3,5-DIIODOPHENYL]-L-ALANINE PENTAHYDRATE
3-[4-(4-HYDROXY-3,5-DIIODOPHENOXY)-3,5-DIIODOPHENYL]-L-ALANINE SODIUM SALT PENTAHYDRATE
L-THYROXINE SODIUM PENTAHYDRATE
L-THYROXINE SODIUM SALT PENTAHYDRATE
(S)-2-AMINO-3-[4-(4-HYDROXY-3,5-DIIODOPHENOXY)-3,5-DIIODOPHENYL]PROPIONIC ACID SODIUM SALT PENTAHYDRATE
SODIUM LEVOTHYROXINE PENTAHYDRATE
SODIUM (S)-2-AMINO-3-[4-(4-HYDROXY-3,5-DIIODOPHENOXY)-3,5-DIIODOPHENYL]PROPIONATE PENTAHYDRATE
3-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)-alaninmonosodiumsa
lt,pentahydrate,
l-tyrosine,o-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-,sodiumsalt,pentahydra
o-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-l-tyrosinesodiumsaltpentahydrate
L-thyroxine sodium pentahydrate*gamma-irradiated
sodium L-4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodobenzylalaninate pentahydrate
L-THYROXINE, SODIUM SALT PENTAHYDRATE, 9 9%
L-THYROXINE SODIUM PENTAHYDRATE*GAMMA-IR RADIATED CE
L-Thyroxinesodiumsaltpentahydratecrystalline
3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]-l-alanine sodium salt
O-(4-Hydroxy-3,5-diiodophenyl)-3,5-diiodo-L-tyrosine monosodium salt pentahydrate
SODIUM L-THYROXINE PENTAHYDRATE
物理化学性质
| 熔点 | 207-210 (dec.)(lit.) |
| 比旋光度 | [α]D20 +15～+19° |
| 密度 | 2.381 |
| 储存条件 | 2-8°C |
| 溶解度 | cell culture medium: 0.1 mg/mL |
| 形态 | powder |
| 形态 | 粉末 |
| 颜色 | 白色到黄色到橙色 |
| 生物来源 | synthetic (organic) |
| BRN | 5721845 |
| CAS 数据库 | 6106-07-6(CAS DataBase Reference) |
安全数据
| 危险性符号(GHS) |  GHS08 |
| 警示词 | 危险 |
| 危险性描述 | H372 |
| 防范说明 | P260-P264-P270-P314-P501 |
| 危险品标志 | Xn |
| 危险类别码 | 40 |
| 安全说明 | S22-S24/25 |
| WGK Germany | 3 |
| RTECS号 | YP2833760 |
| F | 3-8-10 |
图谱信息
左旋甲状腺素钠五水合物(6106-07-6)核磁图(1HNMR)左旋甲状腺素钠五水合物(6106-07-6)红外图谱(IR)左旋甲状腺素钠五水合物(6106-07-6)Raman光谱左旋甲状腺素钠五水合物(6106-07-6)傅里叶红外光谱图知名试剂公司产品信息
左旋甲状腺素钠五水合物价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2026/06/05 | HY-18341AR | 左旋甲状腺素钠五水合物 L-Thyroxine sodium salt pentahydrate (Standard) | 6106-07-6 | 10 mg | 320元 |
| 2026/06/05 | HY-18341AR | 左旋甲状腺素钠五水合物 L-Thyroxine sodium salt pentahydrate (Standard) | 6106-07-6 | 25 mg | 570元 |
| 2026/06/05 | HY-18341AR | 左旋甲状腺素钠五水合物 L-Thyroxine sodium salt pentahydrate (Standard) | 6106-07-6 | 50 mg | 860元 |
常见问题列表
Thyroid Hormone Receptor
Deiodinases (DIOs), which catalyse the conversion of thyroxine (pro-hormone) to the active thyroid hormone, are associated with thyroid stimulating hormone (TSH) levels. DIO1 and DIO2 catalyze activation of thyroid hormone secretion in contrast to DIO3 playing role inactivation of the secretion. Activities of DIO1 and DIO2 play pivotal role in the negative feedback regulation of pituitary TSH secretion. L-Thyroxine (T4) and Triiodothyronine (T3) hormones are known to modulate the expression of ionic channels, pumps and regulatory contractile proteins. Moreover, thyroid hormones have been shown to influence calcium homeostasis and flux responsible for excitation and contractility, with L-Thyroxine and Triiodothyronine modulating its pharmacological control and secretion. In rats fed 12 weeks with the iodine-free diet, a significant decrease in the levels of both Triiodothyronine and L-Thyroxine is observed when compared to the control group fed with standard diet (p<0.001). In the group treated with low doses of L-Thyroxine, an increase in L-Thyroxine levels is observed (p=0.02) while Triiodothyronine levels remain virtually similar to the control group (p=0.19). Rats treated with high doses of L-Thyroxine display a significant increase in both Triiodothyronine and L-Thyroxine circulating concentrations compared to the non-treated hypothyroid group (p<0.001 and p=0.004, respectively) and a significant increase in L-Thyroxine levels when compared to the control values (p=0.03).